Literature DB >> 22821823

Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo.

Siddharth Jhunjhunwala1, Giorgio Raimondi, Andrew J Glowacki, Sherri J Hall, Dan Maskarinec, Stephen H Thorne, Angus W Thomson, Steven R Little.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22821823      PMCID： PMC3491880          DOI： 10.1002/adma.201202513

Source DB:  PubMed          Journal:  Adv Mater        ISSN： 0935-9648            Impact factor:   30.849


× No keyword cloud information.
  24 in total

1.  Regulatory T cells dynamically control the primary immune response to foreign antigen.

Authors:  Dipica Haribhai; Wen Lin; Lance M Relland; Nga Truong; Calvin B Williams; Talal A Chatila
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 2.  Orchestrating the orchestrators: chemokines in control of T cell traffic.

Authors:  Shannon K Bromley; Thorsten R Mempel; Andrew D Luster
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

Review 3.  Regulatory T cells and immune tolerance.

Authors:  Shimon Sakaguchi; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono
Journal:  Cell       Date:  2008-05-30       Impact factor: 41.582

4.  NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.

Authors:  Adam W Mailloux; M Rita I Young
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 5.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 6.  Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

Authors:  Todd M Brusko; Amy L Putnam; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

7.  A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices.

Authors:  Sam N Rothstein; William J Federspiel; Steven R Little
Journal:  Biomaterials       Date:  2008-12-19       Impact factor: 12.479

Review 8.  Human T regulatory cell therapy: take a billion or so and call me in the morning.

Authors:  James L Riley; Carl H June; Bruce R Blazar
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

9.  Delivery of rapamycin to dendritic cells using degradable microparticles.

Authors:  S Jhunjhunwala; G Raimondi; A W Thomson; S R Little
Journal:  J Control Release       Date:  2008-10-26       Impact factor: 9.776

10.  Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease.

Authors:  Blythe D Sather; Piper Treuting; Nikole Perdue; Mike Miazgowicz; Jason D Fontenot; Alexander Y Rudensky; Daniel J Campbell
Journal:  J Exp Med       Date:  2007-06-04       Impact factor: 14.307
View more
  24 in total

Review 1.  Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.

Authors:  James D Fisher; Abhinav P Acharya; Steven R Little
Journal:  Clin Immunol       Date:  2015-05-01       Impact factor: 3.969

2.  IL-4/CCL22/CCR4 axis controls regulatory T-cell migration that suppresses inflammatory bone loss in murine experimental periodontitis.

Authors:  Ana Claudia Araujo-Pires; Andreia Espindola Vieira; Carolina Favaro Francisconi; Claudia Cristina Biguetti; Andrew Glowacki; Sayuri Yoshizawa; Ana Paula Campanelli; Ana Paula Favaro Trombone; Charles S Sfeir; Steven R Little; Gustavo Pompermaier Garlet
Journal:  J Bone Miner Res       Date:  2015-03       Impact factor: 6.741

3.  Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

Authors:  Michelle L Ratay; Andrew J Glowacki; Stephen C Balmert; Abhinav P Acharya; Julia Polat; Lawrence P Andrews; Morgan V Fedorchak; Joel S Schuman; Dario A A Vignali; Steven R Little
Journal:  J Control Release       Date:  2017-05-10       Impact factor: 9.776

Review 4.  Restoring host-microbe homeostasis via selective chemoattraction of Tregs.

Authors:  G P Garlet; C S Sfeir; S R Little
Journal:  J Dent Res       Date:  2014-07-23       Impact factor: 6.116

Review 5.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 6.  Combinatorial drug delivery approaches for immunomodulation.

Authors:  Joshua M Stewart; Benjamin G Keselowsky
Journal:  Adv Drug Deliv Rev       Date:  2017-05-19       Impact factor: 15.470

7.  Engineering immunomodulatory biomaterials for type 1 diabetes.

Authors:  C L Stabler; Y Li; J M Stewart; B G Keselowsky
Journal:  Nat Rev Mater       Date:  2019-05-17       Impact factor: 66.308

Review 8.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

Review 9.  Controlled release strategies for modulating immune responses to promote tissue regeneration.

Authors:  Courtney M Dumont; Jonghyuck Park; Lonnie D Shea
Journal:  J Control Release       Date:  2015-08-08       Impact factor: 9.776

Review 10.  Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease.

Authors:  Andrew J Glowacki; Riccardo Gottardi; Sayuri Yoshizawa; Franco Cavalla; Gustavo P Garlet; Charles Sfeir; Steven R Little
Journal:  Ann Biomed Eng       Date:  2014-09-23       Impact factor: 3.934
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.